SEARCH

SEARCH BY CITATION

Keywords:

  • oropharyngeal cancer;
  • human papillomavirus;
  • p16;
  • epidermal growth factor receptor;
  • survival

Abstract

  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. References

Molecular prognostic indicators for oropharyngeal squamous cell carcinoma (OSCC), including HPV-DNA detection, epidermal growth factor receptor (EGFR) and p16 expression, have been suggested in the literature, but none of these are currently used in clinical practice. To compare these predictors, 106 newly diagnosed OSCC for the presence of HPV-DNA and expression of p16 and EGFR were analyzed. The 5-year disease-free survival (DFS) and overall survival (OS) were calculated in relation to these markers and a multivariate Cox analysis was performed. Twenty-eight percent of the cases contained oncogenic HPV-DNA and 30% were positive for p16. The p16 expression was highly correlated with the presence of HPV-DNA (p < 0.001). Univariate analysis of the 5-year DFS revealed a significantly better outcome for patients with p16-positive tumors (84% vs. 49%, p = 0.009). EGFR-negative tumors showed a tendency toward a better prognosis in DFS (74% vs. 47%, p = 0.084) and OS (70% vs. 45%, p = 0.100). Remarkable and highly significant was the combination of p16 and EGFR expression status, leading to 5-year DFS of 93% for p16+/EGFR− tumors vs. 39% for p16−/EGFR+ tumors (p = 0.003) and to a 5-year OS of 79% vs. 38%, respectively (p = 0.010). In multivariate analysis p16 remained a highly significant prognostic marker for DFS (p = 0.030) showing a 7.5-fold increased risk for relapse in patients with p16-negative tumors. Our data indicate that p16 expression is the most reliable prognostic marker for OSCC and further might be a surrogate marker for HPV-positive OSCC. HPV+/p16+ tumors tended to have decreased EGFR expression, but using both immunohistological markers has significant prognostic implications. © 2007 Wiley-Liss, Inc.

Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer worldwide, with more than 300,000 cases occurring in the oral cavity and pharynx every year.1 Despite a decreasing occurrence of most tumors of the upper aerodigestive tract in developed countries, reflecting a reduced exposure to alcohol and tobacco, the incidence of oropharyngeal squamous cell carcinoma (OSCC) has been found to be on the rise.2, 3 Overall prognosis of HNSCC has not been improved in recent years. Only the implementation of multimodal treatment regimes has resulted in a slight favorable prognosis for the oropharyngeal subset in the last decade.4

Insight into genetic and molecular alterations in the development of head and neck cancer research has grown explosively in recent years. As a consequence potential molecular and prognostic markers and new targets for cancer treatment have been proposed, and there is hope that individualized cancer treatment based on these molecular targets will improve prognosis and decrease side effects.

Over the last 5 years it has become clear that a subset of OSCC is associated with oncogenic human papillomavirus (HPV), in particular HPV type 16.5, 6, 7 HPV-positive OSCC furthermore differ from HPV-negative tumors with respect to tumor differentiation,8, 9 risk factors10 and genetic changes,6, 11 indicating that HPV-positive OSCC represent a separate tumor entity12 and that at least 2 molecular pathways leading to OSCC exist.1 On basis of HPV-DNA detection by PCR, the presence of HPV has been associated with a favorable prognosis in many studies,13, 14, 15 although some studies did not find this relation.16, 17 This discrepancy may be due to the fact that not all HPV-DNA-positive OSCC show viral oncogene expression, which is believed to be essential in HPV related carcinogenesis and tumor progression. Therefore, the biological meaning of HPV-DNA detection is doubtful in these cases.18, 19

The p16 protein inactivates the function of cdk4- and cdk6-cyclin D complexes. One of the critical substrates of the G1-specific cdk complexes is the release of E2F through phosphorylation of the retinoblastoma (pRb)-E2F protein complex.20 Hence, p16 negatively regulates cell proliferation by suppression of hyperphosphorylation of pRb.21, 22 On the other hand, pRb acts as a negative regulator of p16 expression.23 Functional loss of p16 has been demonstrated in a wide variety of tumors.24 In contrast, in HPV associated cancer p16 inactivation is rare.25 Moreover, p16 overexpression has been observed in squamous cell carcinomas and dysplasia of the cervix.26 This is in line with the fact that the viral oncoprotein E7 inactivates the pRb protein, which would otherwise inhibit p16 transcription, and with recent reports and our previous results showing highly increased p16 expression in HPV-positive OSCC.6, 9, 18, 27, 28, 29, 30 In contrast, frequent p16 inactivation by transcriptional silencing or genetic changes has been reported for HPV-independent HNSCC,31 and chromosome 9p21 abnormalities were reported as early events in the development of HNSCC.32 In parallel to that are some studies reporting a decreased survival for OSCC patients where p16 is inactivated regardless of HPV-DNA detection.33

In addition to p16 as a potential prognostic marker for OSCC the expression of the epidermal growth factor receptor (EGFR) has been in focus as a molecular marker. EGFR is a transmembrane tyrosine kinase receptor of the erbB-family that is normally expressed at low levels on the surface of most normal cells. A variety of studies have shown that EGFR is overexpressed in HNSCC.34, 35 Overexpression of EGFR has been associated with a more aggressive clinical behavior, resistance to treatment and a poor prognosis.36, 37 Recently also quantitative determination of EGFR expression could be correlated to prognosis in OSCC.38

Despite the indicated potence as prognostic markers for OSCC, no studies have been performed to analyze their combination. Here we examine the combination of the most promising predictive markers for OSCC, including HPV-DNA detection, p16 and EGFR expression, in a series of primary OSCC.

Material and methods

  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. References

Subjects and material

We retrospectively analyzed formalin-fixed, paraffin-embedded tissue from 106 consecutive patients with newly diagnosed and histologically confirmed squamous cell carcinoma of the oropharynx treated at the hospital of the University of Cologne between January 1997 and December 2002. Twenty-five of these cases were the subject of a previous publication.30 Patients' ages ranged from 43 to 80 years (median age 59 years). Eighty-three patients were males (78%) and twenty-three were females (22%). Tumor staging was assessed according to the 2002 American Joint Committee on Cancer staging criteria.39 Three percent of the patients presented at stage I, 14% at stage II, 18% at stage III, 54% at stage IVa and 9% at stage IVb. Two patients (2%) had distant metastases (stage IVc) at the time of diagnosis.

Tumor specimens of all cases were obtained during surgery, immediately frozen in liquid nitrogen, and stored at −80°C. In addition, tissue was fixed in 4% buffered formalin and embedded in paraffin by routine procedures in the Department of Pathology of the University of Cologne. Slides from all blocks were reviewed by one pathologist (H.U.K.) to select the most representative areas of the tumors for further processing and for immunohistochemistry. The criteria for block selection were to take vital tumor tissue without necrosis and to have a front of invasion. Only blocks with estimates of at least 70% tumor cells were included.

HPV16-positive cervical carcinoma specimens were used as positive controls. Histological grading was performed in a blind manner following the WHO criteria for squamous cell carcinomas of the oral mucosa.40

Sample preparation, polymerase chain reaction and HPV typing

Tissues were processed as previously described.8 After confirming integrity of DNA by β-globin gene PCR,41 HPV sequences were detected by highly sensitive nested PCR protocols with degenerated primers A10/A5-A6/A8 for HPV group A (genital/mucosal) HPVs42 and CP62/70-CP65/69a for group B1 (cutaneous/EV) HPVs.43 PCR products (10 l) were separated in 2% agarose gels and visualized by ethidium bromide staining. HPV typing was performed as described previously.8

Immunohistochemical staining

Ninety-six cases in the study group were eligible for immunohistochemical staining similar to that described previously.18 In each case, 2–3 m sections of formalin-fixed and paraffin-embedded biopsy samples were processed by the avidin–biotinylated–peroxidase complex (ABC) method (Chem Mate Detection kit; Dako Cytomation, Carpinteria, CA). Sections were dewaxed by passage through xylene and rehydrated by a graded series of ethanol, followed by microwave treatment for antigen retrieval, which was for p16 staining 2 times 7 minutes at 600 Watts in 10 mM citrate buffer (pH 6.0) and for EGFR staining 20 minutes in Pepsin at room temperature (Pepsin solution Digest-All3, Zymed). After a brief rinse with tris-buffer (BUF1), they were incubated with the primary antibody for 25 minutes (p16: Ab-4, clone 16P04 Neo Markers, Fremont, CA; EGFR: EGFR, clone 31G7 Zytomed). After another brief rinse with tris-buffer (BUF1), the tissue was incubated with the biotinylated secondary antibody for another 25 minutes. After a brief rinse with tris-buffer (BUF2), the endogenous peroxidase was inactivated with peroxidase-blocking solution, 3 times for 2½ minutes each. After rinsing, the tissues were incubated for another 25 minutes with Streptavidin conjugated with horseradish-peroxidase. Visualization was performed with 3-Amino-9-Ethylcarbazol (AEC, Dako Cytomation, Carpinteria, CA) 3 times for 5 minutes, and sections were counterstained with hematoxylin. Nondysplastic, peritonsillar squamous cell epithelium was used as a negative control.

Strong nuclear staining as well as strong cytoplasmic staining was considered positive for p16 expression. P16 immunostaining was regarded as overexpression if it was strong and diffuse and more than 60% of the tumor cells were p16-positive. EGFR expression was regarded as positive when more than 50% of the cell membranes of the tumor cells were completely stained. Cytoplasmatic staining was not considered for this stratification.

Statistical analysis

P16, EGFR and HPV status were analyzed using cross-tabulations and χ2 test with the SPSS Base System, version 11.0 (SPSS, Chicago, IL). Disease-free survival and overall survival rates were estimated using the Kaplan–Meier algorithm for incomplete observations. Twenty-six patients were excluded from survival analysis because of the presence of stage IVc disease, unresectable tumor, incomplete curative treatment or R2 resection margin, or because they never achieved disease free status. The overall survival time was defined as the interval between the date of diagnosis and the last date when the patient was known to be alive (censored) or date of death for any reason (uncensored). The disease-free survival rate was measured as the period of time between the date of diagnosis and the date of the last follow-up examination in which the patient was disease-free (censored), or the date of first recurrence independently if it was a local, regional or distant recurrence (uncensored). The log rank test was used to test for differences between subgroups. A p-value ≤0.05 was considered statistically significant in 2-sided tests.

Results

  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. References

HPV status and HPV typing

Sequences of high-risk HPV were detected in DNA preparations for 30 (28%) out of 106 oropharyngeal carcinoma cases. Of these positive cases, 29 (97%) carried HPV16 and 1 (3%) HPV33 sequences. In 2 of the cases (7%), additional infection with low-risk HPV was detected. HPV-positive tumors showed significantly poorer differentiation than HPV-negative tumors (p = 0.022, Table I).

Table I. Associations Between Tumor's Biologic Markers and Patient's Clinicopathologic Characteristics [Number/Total Number (%)]
CharacteristicsHPV-positive (%)p16-positive (%)EGFR-positive (%)
  1.  n.a. = not accessible. Of the 106 patients, 96 cases of the study group were eligible for immunohistochemical staining.

Gender   
 Male21/83 (25)21/74 (28)39/74 (53)
 Female9/23 (39)8/22 (36)7/22 (32)
 p value0.1930.4740.085
Tumor stage   
 Stage I1/4 (25)1/3 (33)2/4 (50)
 Stage II3/15 (20)3/14 (21)7/14 (50)
 Stage III5/18 (28)4/17 (23.5)3/17 (18)
 Stage IV21/69 (30)20/60 (33)34/61 (56)
 p value0.8760.8200.051
Tumor grade   
 Grade I0/5 (0)0/3 (0)1/3 (33)
 Grade II11/55 (20)10/52 (19)28/52 (35)
 Grade III19/46 (41)19/41 (46)17/41 (41)
 p value0.0220.0090.433
Tumor site   
 Tonsils21/63 (33)21/56 (37.5)27/56 (48)
 Base of tongue3/14 (21)3/13 (23)9/13 (69)
 Others6/29 (21)5/27 (18)10/27 (37)
 p value0.5940.3290.384
Lymph node involvement   
 N+24/74 (32)23/66 (35)33/66 (50)
 N−6/32 (19)6/30 (20)13/30 (43)
 p value0.1510.1420.544
Smoking (n.a., n = 7)   
 +14/80 (17.5)13/71 (18)39/72 (55)
 −14/18 (78)14/17 (82)4/17 (23.5)
 p value0.0000.0000.020
Alcohol (n.a., n = 8)   
 +12/72 (17)10/64 (16)33/64 (52)
 −16/25 (64)17/24 (71)9/24 (37.5)
 p value0.0000.0000.239
Therapy (none, n = 2)   
 Only surgery6/21 (29)6/19 (32)6/19 (32)
 Surgery + RT/RCT20/64 (31)19/56 (34)26/56 (46)
 Definitive + RT/RCT4/19 (21)3/19 (16)13/19 (68)
 p value0.6690.4520.152

Expression of p16

There were 3 different immunostaining phenotypes observed for p16 immunoreactivity, i.e., strong and diffuse cytoplasmic and nuclear staining, weak cytoplasmic and nuclear staining and negative staining for all tumor cells (Fig. 1a). In general, surrounding mesenchymal cells showed no p16 immunoreactivity, except for some weak staining found occasionally in lymphocytes and salivary glands. Nondysplastic, squamous cell epithelium was p16-negative and served as an internal negative control. Interestingly, in most cases (29; 30.2%) p16 was either overexpressed in all malignant cells or totally absent in the tumor (58; 60.4%), whereas the group with weak cytoplasmic and nuclear staining of the tumor cells consisted only of 9 (9.4%) cases.

thumbnail image

Figure 1. (a) EGFR expression in oropharyngeal squamous cell carcinoma, demonstrating strong and diffuse membrane and cytoplasmic staining (magnification ×200). (b) P16 expression in oropharyngeal squamous cell carcinoma, demonstrating strong and diffuse cytoplasmic and nuclear staining (magnification ×200). [Color figure can be viewed in the online issue, which is available at www.interscience.wiley.com.]

Download figure to PowerPoint

P16 overexpression was significantly associated with poorer differentiation of the tumor. Of the p16-positive cases, 19 (65.5%) were poorly differentiated, whereas of the p16-negative cases only 33% showed poor differentiation (p = 0.009; Table I).

Expression of EGFR

The EGFR staining was more heterogenous compared with the pattern observed for the p16 staining (Fig. 1b). Membranes and cytoplasm of the tumor cells showed variable staining intensities in different cases. For the EGFR staining, the number of immunopositive cancer cells ranged from 0% to 100%. Using the above described evaluation criteria, 46 (43%) of the OSCC cases showed EGFR overexpression.

Comparison of the tumor stage with EGFR expression suggested a correlation between EGFR expression and advanced tumor stage (p = 0.051, Table I). However, this trend was only the result of the low rate of EGFR-positive tumors in patients with stage III disease (Table I). In comparisons between stage I–III and stage IV the correlation between EGFR expression and advanced tumor stage became significant (p = 0.043).

Correlation of HPV-DNA detection and immunhistochemistry

The correlation between p16 expression and the prevalence of oncogenic HPV-DNA in the tumor cells was highly significant (p < 0.001, Table II). Additionally, the study results showed a trend toward an inverse correlation of the p16 and EGFR expression in terms that p16-positive OSCC showed less EGFR expression (p = 0.083); however, this trend did not reach statistical significance. No significant correlation was revealed between EGFR expression and HPV status (p = 0.125).

Table II. Correlation Between the Presence of P16 Expression and the Presence of the Parameters HPV-DNA and EGFR Expression in OSCC [Number/Total Number (%)]
 P16+ (29/96)P16− (67/96)
HPV+25/29 (86)2/67 (3)
HPV−4/29 (14)65/67 (97)
p value (HPV × P16) <0.001  
EGFR+10/29 (34.5)36/67 (54)
EGFR−19/29 (65.5)31/67 (46)
p value (EGFR × P16) 0.083  

Survival analysis

For survival analysis, 26 patients were excluded as described above, including 7 (27%) HPV-positive and p16-negative cases. HPV-containing tumors showed a tendency toward a better 5-year disease-free survival rate (74%) compared with the HPV-lacking group (53%, p = 0.083; Table III). In an analysis of overall survival, the 5-years' probability of HPV-positive tumors was 70%, compared with 51% for HPV-negative tumors, which was not significant (p = 0.231).

Table III. Univariate 5-Year Overall Survival and Disease-Free Survival Analysis for Clinical Characteristics and Markers
ParametersOverall survival (%) (95% CI)p valueDisease-free survival(%) (95% CI)p value
  1.  Twenty six patients were excluded from survival analysis because of having stage IVc disease, unresectable tumor, incomplete curative treatment, R2 resection margin or never achieving disease free status.

Stage 1–371 (52–90) 64 (43–85) 
Stage 449.5 (35–64)0.10057 (41–72)0.635
N+ limited85 (69–101) 65 (40–90) 
N+ extended42 (26–59)0.00952 (40–74)0.201
Differentiation    
 Well50 (−19 to 119)0.33567 (13–120)0.520
 Moderately52 (36–68)0.04553 (35–70.5)0.165
 Poorly66 (50–83) 68 (52–85) 
p16+73 (54–91) 84 (67–101) 
p16−49 (33–65)0.07049 (31–66)0.009
EGFR+45 (27–63) 47 (27–66) 
EGFR−70 (56–85)0.10074 (58–90)0.084
HPV+70 (51–89) 74 (54–94) 
HPV−51 (36–65)0.23153 (37–68)0.083
EGFR+/p16−38 (17–59) 39 (16–62) 
EGFR−/p16+79 (57–100)0.01093 (79–106)0.003

Patients with p16 overexpression in their tumors had a significantly better 5-year disease-free survival rate, namely, 84% compared with 49% for patients with p16-negative tumors (p = 0.009, Fig. 2a; Table III). Although not statistically significant, patients with p16-positive tumors also tended to have better overall survival rate than those with p16-negative tumors (73% vs. 49%, p = 0.070, Fig. 2b). Better disease-free and overall survival rates were also seen for those patients who were treated only by surgery (21 cases), but reached no statistical difference in this small subgroup.

thumbnail image

Figure 2. Univariate survival analysis by p16 tumor status and by the combination of EGFR and p16 expression. Disease-free survival (a and c) and overall survival (b and d) curves based on the Kaplan–Meier method were analyzed.

Download figure to PowerPoint

Patients with EGFR-overexpressing tumors showed a rather poor disease-free survival rate (47%), while cases with absent EGFR-expression tended toward a better prognosis (74%, p = 0.084). Statistically similar results were obtained for the 5-years' probability for the overall survival which was 45% versus 70% (p = 0.100) for the EGFR-negative and positive cases, respectively. However, neither estimate reached statistical significance.

The combination of p16 and EGFR as predictor for survival was tested. Comparing the EGFR-positive and p16-negative patient group with the EGFR-negative and p16-positive group turned out to be significant. Of all patients 43.4% were either p16+/EGFR− or p16−/EGFR+.

For patients with EGFR+/p16− tumors, the 5-year disease-free survival rate was 39%, while the survival rate of patients with EGFR−/p16+ tumors was 93% (p = 0.003, Fig. 2c). The 5-year overall survival rate for the EGFR+/p16− group was poor (38%), compared with the EGFR−/p16+ group, which showed a significantly better outcome (79%, p = 0.010, Fig. 2d).

Multiregression

Using the Cox proportional hazards model, we performed a multivariate analysis to assess the independent predictive value of all markers and the promising combination of p16 and EGFR for overall- and disease-free survival. The following prognostic variables were included in the model: HPV, p16, EGFR and tumor stage (Table IV). P16 expression status was revealed as an independent and significant prognostic factor for disease-free survival in this model (p = 0.030). In terms of overall survival, p16 expression status showed a trend but was not significant (p = 0.059, Fig. 3). All other included variables were not significant (Table IV).

thumbnail image

Figure 3. Disease-free survival (a) and overall survival (b) in multivariate analysis. Disease-free survival and overall survival curves based on the Cox proportional hazard model were analyzed. The survival curves distinguish p16 positive and negative cases with all other parameters being equal for the cohort.

Download figure to PowerPoint

Table IV. Multivariate Overall Survival and Disease-Free Survival for Clinical Characteristics and Markers, Using the Cox Proportional Hazard Model
VariablesHazard ratio95% CIp value
  1.  n.a., not accessible.

Disease-free survival   
 hpv (−/+)0.340.06–1.850.213
 p16 (−/+)7.51.22–46.190.030
 EGFR (−/+)1.120.51–2.420.784
 Stage (1/4)n.a.n.a.0.974
 Stage (2/4)0.530.17–1.600.260
 Stage (3/4)0.650.23–1.800.404
Overall survival   
 hpv (−/+)0.420.10–1.760.235
 p16 (−/+)4.190.95–18.570.059
 EGFR (+/−)1.140.60–2.150.692
 Stage (1/4)0.97n.a.0.971
 Stage (2/4)0.060.13–1.040.060
 Stage (3/4)0.190.21–1.370.194

Discussion

  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. References

Oropharyngeal cancers are a heterogenious group of malignancies in terms of etiology, biological behavior and prognosis.44 Although many clinicopathological parameters have been indicated to predict prognosis, no such markers are used in clinical practice today, apart from TNM staging. However, recent insights in molecular changes underlying HNSCC development have identified new potential prognostic indicators, such as p16, EGFR and HPV status. The existing data regarding the prognostic significance of p16 in HNSCC are controversial. In carcinoma of the anterior tongue45 as well as in tonsillar carcinoma30 and OSCC,46 loss of p16 expression has been found to be associated with a worse prognosis. In contrast, other studies have found no prognostic significance of p16 inactivation in HNSCC of different localizations.47, 48 This might be due to differences in tumor biology within the different mucosal regions of the head and neck. In addition, a discrepancy exists with respect to the meaning of EGFR overexpression in OSCC. Some studies have found no correlation between survival and EGFR expression,49, 50 whereas others showed a favorable outcome for the EGFR-negative group of OSCC.51

Our previous studies and others have shown that at least one third of OSCC are infected by oncogenic HPV,6, 7, 8, 52 predominantly HPV type 16. In this study, only 28% of the tumors were HPV-positive, even though others had found a higher prevalence of HPV-positive tumors in OSCC.6, 28, 53, 54 This discrepancy could be the result of varying numbers of exact anatomical stratification of the lesions within the oropharynx and the use of different detection methods. However, since multiple and nested PCR assays were used for HPV-DNA detection in this study, it is unlikely that we missed any HPV-positive cases in our series. Serologic studies have demonstrated that HPV16-positive subjects have an increased risk for the development of oropharyngeal carcinoma.55, 56 Recently, the specific T-cell response to HPV16 E7 epitopes in subjects with HPV16 E7 expressing and p16-positive OSCC was shown.57 Evidence is growing that HPV-DNA detection in OSCC can be used as predictor for prognosis14, 58, 59 which might be attributed to a higher sensitivity to radiation therapy.15

To the best of our knowledge the current study is the first combining the most promising predictive markers HPV-DNA detection, p16 and EGFR expression in a large series of primary OSCC. We found that p16 expression is highly correlated with the presence of HPV-DNA in OSCC, which confirms our results for tonsillar cancer.6, 30 This is in line with the hypothesis that in HPV-positive tumors p16 is upregulated because of the interaction of the HPV16 E7 oncogene product with the pRb protein, which would otherwise inhibit p16 transcription. The interaction of the presence of HPV-DNA in the tumor and clear p16 overexpression, and, respectively, the absence of HPV-DNA and the loss of p16, was seen in 94 of 100 OSCC. Of this set, only 2 tumors were HPV-positive but p16-negative, and both of them occurred in strong smokers consuming more than 22 packs per year. It could be argued that exposure to this additional risk factor imposed, additional genetic or especially epigenetic changes yielding to loss of p16 which overcame the HPV16 E7 effects. Because of the lack of fresh tissue in these cases it was not possible to further analyze this possibility. However, from a clinical point of view both of these cases had a rather bad outcome with tumor recurrence after 7 months for 1 and 12 months for the other. This result would be in line with the predictive potential of p16 overexpression even in HPV-positive cases. Four cases of our batch were HPV-negative but expressed the p16 protein, and two of them did not meet the inclusion criteria for survival analysis. The 2 remaining cases were free of recurrence for 49 and 50 months. Thus, the presence of p16 expression also predicts a rather favorable outcome in these cases.

P16 expression was found to be a strong independent prognostic factor for 5-year disease-free survival and showed a tendency for better 5-year overall survival. In multivariate Cox analysis, p16 remained to be an independent prognostic factor. The prediction for disease-free survival of p16 expression was superior to all clinicopathological parameters normally used for treatment decisions and assessment of prognosis. In the current study population, patients with p16-negative OSCC had a 4-fold increase in their risk of death from any cause, and a 7.5-fold increased risk of recurring cancer, compared with patients with p16-positive tumors. Despite the increased outcome of p16-positive and HPV-positive tumors, they were more likely to be poorly differentiated. Furthermore, no correlation was detected between tumor grading and prognosis. Therefore, the data suggest that the general rule that higher histological grade implicates decreased prognosis is not the case for the p16-positive OSCC.

However, EGFR expression did not reach significant levels in either univariate or multivariate analysis. The EGFR-positive cases tended to have worse 5-year disease-free survival and worse 5-year overall survival rates compared with EGFR-negative cases. In univariate analysis, the comparison of the p16+/EGFR− group with the p16−/EGFR+ group revealed a significant difference for both 5-year disease-free survival (p = 0.003) and 5-year overall survival (p = 0.010) rates.

To our knowledge, this is the first series showing a tendency for an inverse correlation of p16 and EGFR expression in OSCC. The molecular explanation for this interaction remains unclear and is not the subject of this study. Reported interaction of HPV proteins with EGFR has shown that HPV-E5 expression leads to elevated EGFR expression in cell culture models.60 Therefore, it is likely that EGFR overexpression in our series is HPV independent.

In our series of OSCC, the multimodal treatment regime included postoperative or definitive radiation in 80% of the patients. The prognostic differences with the used immunohistochemical markers were also found in the tumors of patients treated only surgically. This subgroup was too small to allow further analysis of the involvement of the therapy chosen. Therefore, it remains unclear whether the favorable outcome of p16-positive cases was attributed to higher radiosensitivity, as recently postulated.61

As a future perspective, it might be possible to improve therapeutic outcome in tumors with inactive p16 by restoration of p16 activity or the use of cdk4 inhibitors. Such inhibitors are already used in combination with chemotherapy in clinical trials and show promising results.62, 63, 64 P16 adenovirus-mediated gene therapy has also successfully been applied against HNSCC in vivo.65, 66, 67 Concerning EGFR, several approaches for targeted therapy have been tried. Approaches with antigen specific monoclonal antibodies and small molecule kinase inhibitors look especially promising. Some of these agents have already been approved for the treatment of epithelial cancer.68 Future studies will have to show whether the marker tested in the current study will be useful to select patients for these adjuvant therapies.

In conclusion, p16 is a strong, independent prognostic indicator in patients with oropharyngeal tumors. P16 immunoreactivity is most likely the result of transcriptionally active HPV infection and therefore p16 expression is highly correlated with HPV status in OSCC. Furthermore, our data indicate that p16 may be a more powerful marker than HPV-DNA detection for predicting prognosis. However, other studies have shown that detection of HPV-DNA by PCR was a significant predictor for disease free survival as well as overall survival.14, 53, 54, 69

For clinicians, combined immunohistochemistry of p16 and EGFR is both easily applicable in a routine pathology laboratory, and it provides important prognostic information for the individual patient with more relevance than staging alone. As it was shown in some studies for OSCC, the outcome of primary radiation with salvage neck dissection was equal to surgery with postoperative radiation.70 Further studies have to show whether, for p16+/EGFR− OSCC, the appropriate treatment of the primary tumor might be radiochemotherapy alone. Therefore, these markers might not only be of prognostic significance but may also become the basis of treatment decisions in the future.

References

  1. Top of page
  2. Abstract
  3. Material and methods
  4. Results
  5. Discussion
  6. References
  • 1
    Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol 2004; 31: 74454.
  • 2
    Frisch M,Hjalgrim H,Jaeger AB,Biggar RJ. Changing patterns of tonsillar squamous cell carcinoma in the United States. Cancer Causes Control 2000; 11: 48995.
  • 3
    Shiboski CH,Schmidt BL,Jordan RC. Tongue and tonsil carcinoma: increasing trends in the US population ages 20–44 years. Cancer 2005; 103: 18439.
  • 4
    Carvalho AL,Nishimoto IN,Califano JA,Kowalski LP. Trends in incidence and prognosis for head and neck cancer in the United States: a site-specific analysis of the SEER database. Int J Cancer 2005; 114: 80616.
  • 5
    Klussmann JP,Dinh S,Guntinas-Lichius O,Wittekindt C,Weissenborn S,Wieland U,Dienes HP,Hoffmann T,Smith E,Turek L,Speel EJ,Pfister HJ. HPV-associated tonsillar cancer. An update. HNO 2004; 52: 20818.
  • 6
    Hafkamp HC,Speel EJ,Haesevoets A,Bot FJ,Dinjens WN,Ramaekers FC,Hopman AH,Manni JJ. A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8. Int J Cancer 2003; 107: 394400.
  • 7
    Gillison ML,Lowy DR. A causal role for human papillomavirus in head and neck cancer. Lancet 2004; 363: 14889.
  • 8
    Klussmann JP,Weissenborn S,Wieland U,Dries V,Kolligs J,Jungehuelsing M,Eckel HE,Dienes HP,Pfister H,Fuchs P. Prevalence, distribution and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer 2001; 92: 287584.
  • 9
    Wilczynski SP,Lin BT,Xie Y,Paz IB. Detection of human papillomavirus DNA and oncoprotein overexpression are associated with distinct morphological patterns of tonsillar squamous cell carcinoma. Am J Pathol 1998; 152: 14556.
  • 10
    Smith EM,Ritchie JM,Summersgill KF,Klussmann JP,Lee JH,Wang D,Haugen TH,Turek LP. Age, sexual behavior and human papillomavirus infection in oral cavity and oropharyngeal cancers. Int J Cancer 2004; 108: 76672.
  • 11
    Balz V,Scheckenbach K,Gotte K,Bockmuhl U,Petersen I,Bier H. Is the p53 inactivation frequency in squamous cell carcinomas of the head and neck underestimated? Analysis of p53 exons 2-11 and human papillomavirus 16/18 E6 transcripts in 123 unselected tumor specimens. Cancer Res 2003; 63: 118891.
  • 12
    Klussmann JP,Weissenborn SJ,Wieland U,Dries V,Eckel HE,Pfister HJ,Fuchs PG. Human papillomavirus-positive tonsillar carcinomas: a different tumor entity? Med Microbiol Immunol (Berl) 2003; 192: 12932.
  • 13
    Li W,Thompson CH,O'Brien CJ,McNeil EB,Scolyer RA,Cossart YE,Veness MJ,Walker DM,Morgan GJ,Rose BR. Human papillomavirus positivity predicts favourable outcome for squamous carcinoma of the tonsil. Int J Cancer 2003; 106: 5538.
  • 14
    Ritchie JM,Smith EM,Summersgill KF,Hoffman HT,Wang D,Klussmann JP,Turek LP,Haugen TH. Human papillomavirus infection as a prognostic factor in carcinomas of the oral cavity and oropharynx. Int J Cancer 2003; 104: 33644.
  • 15
    Lindel K,Beer KT,Laissue J,Greiner RH,Aebersold DM. Human papillomavirus positive squamous cell carcinoma of the oropharynx: a radiosensitive subgroup of head and neck carcinoma. Cancer 2001; 92: 80513.
  • 16
    Pintos J,Franco EL,Black MJ,Bergeron J,Arella M. Human papillomavirus and prognoses of patients with cancers of the upper aerodigestive tract. Cancer 1999; 85: 19039.
  • 17
    Paz IB,Cook N,Odom-Maryon T,Xie Y,Wilczynski SP. Human papillomavirus (HPV) in head and neck cancer. An association of HPV 16 with squamous cell carcinoma of Waldeyer's tonsillar ring. Cancer 1997; 79: 595604.
  • 18
    Wiest T,Schwarz E,Enders C,Flechtenmacher C,Bosch FX. Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control. Oncogene 2002; 21: 151017.
  • 19
    van Houten VM,Snijders PJ,van den Brekel MW,Kummer JA,Meijer CJ,van Leeuwen B,Denkers F,Smeele LE,Snow GB,Brakenhoff RH. Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas. Int J Cancer 2001; 93: 2325.
  • 20
    Sherr CJ. The INK4a/ARF network in tumour suppression. Nat Rev Mol Cell Biol 2001; 2: 7317.
  • 21
    Kamb A,Gruis NA,Weaver-Feldhaus J,Liu Q,Harshman K,Tavtigian SV,Stockert E,Day RS,III,Johnson BE,Skolnick MH. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264: 43640.
  • 22
    Nobori T,Miura K,Wu DJ,Lois A,Takabayashi K,Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994; 368: 7536.
  • 23
    Li Y,Nichols MA,Shay JW,Xiong Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res 1994; 54: 607882.
  • 24
    Roussel MF. The INK4 family of cell cycle inhibitors in cancer. Oncogene 1999; 18: 531117.
  • 25
    Kim JW,Namkoong SE,Ryu SW,Kim HS,Shin JW,Lee JM,Kim DH,Kim IK. Absence of p15INK4B and p16INK4A gene alterations in primary cervical carcinoma tissues and cell lines with human papillomavirus infection. Gynecol Oncol 1998; 70: 759.
  • 26
    Klaes R,Friedrich T,Spitkovsky D,Ridder R,Rudy W,Petry U,Dallenbach-Hellweg G,Schmidt D,von Knebel DM. Overexpression of p16(INK4A) as a specific marker for dysplastic and neoplastic epithelial cells of the cervix uteri. Int J Cancer 2001; 92: 27684.
  • 27
    Lo ML,D'Angelo M,Procaccini M,Bambini F,Calvino F,Florena AM,Franco V,Giovannelli L,Ammatuna P,Campisi G. Expression of cell cycle markers and human papillomavirus infection in oral squamous cell carcinoma: use of fuzzy neural networks. Int J Cancer 2005; 115: 71723.
  • 28
    Li W,Thompson CH,Cossart YE,O'Brien CJ,McNeil EB,Scolyer RA,Rose BR. The expression of key cell cycle markers and presence of human papillomavirus in squamous cell carcinoma of the tonsil. Head Neck 2004; 26: 19.
  • 29
    Begum S,Gillison ML,Ansari-Lari MA,Shah K,Westra WH. Detection of human papillomavirus in cervical lymph nodes: a highly effective strategy for localizing site of tumor origin. Clin Cancer Res 2003; 9: 646975.
  • 30
    Klussmann JP,Gultekin E,Weissenborn SJ,Wieland U,Dries V,Dienes HP,Eckel HE,Pfister HJ,Fuchs PG. Expression of p16 protein identifies a distinct entity of tonsillar carcinomas associated with human papillomavirus. Am J Pathol 2003; 162: 74753.
  • 31
    Reed AL,Califano J,Cairns P,Westra WH,Jones RM,Koch W,Ahrendt S,Eby Y,Sewell D,Nawroz H,Bartek J,Sidransky D. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996; 56: 36303.
  • 32
    Poi MJ,Yen T,Li J,Song H,Lang JC,Schuller DE,Pearl DK,Casto BC,Tsai MD,Weghorst CM. Somatic INK4a-ARF locus mutations: a significant mechanism of gene inactivation in squamous cell carcinomas of the head and neck. Mol Carcinog 2001; 30: 2636.
  • 33
    Weinberger PM,Yu Z,Haffty BG,Kowalski D,Harigopal M,Sasaki C,Rimm DL,Psyrri A. Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res 2004; 10: 568491.
  • 34
    Santini J,Formento JL,Francoual M,Milano G,Schneider M,Dassonville O,Demard F. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991; 13: 1329.
  • 35
    Dassonville O,Formento JL,Francoual M,Ramaioli A,Santini J,Schneider M,Demard F,Milano G. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993; 11: 18738.
  • 36
    Ciardiello F,Tortora G. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 2001; 7: 295870.
  • 37
    Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002; 20( Suppl 18): 1S13S.
  • 38
    Psyrri A,Yu Z,Weinberger PM,Sasaki C,Haffty B,Camp R,Rimm D,Burtness BA. Quantitative determination of nuclear and cytoplasmic epidermal growth factor receptor expression in oropharyngeal squamous cell cancer by using automated quantitative analysis. Clin Cancer Res 2005; 11: 585662.
  • 39
    Greene FL,Page DL,Fleming ID,Fritz AG,Blach CM,Haller DG,Morrow M. American joint committee on cancer staging manual, 6th edn. Berlin: Springer, 2002.
  • 40
    Pindbord JJ,Reichart PA,Smith CJ,van der Waal I. Histological typing of cancer and precancer of the oral mucosa, 2nd edn. Berlin: Springer, 1997.
  • 41
    de Roda Husman AM,Snijders PJ,Stel HV,van den Brule AJ,Meijer CJ,Walboomers JM. Processing of long-stored archival cervical smears for human papillomavirus detection by the polymerase chain reaction. Br J Cancer 1995; 72: 41217.
  • 42
    Wieland U,Ritzkowsky A,Stoltidis M,Weissenborn S,Stark S,Ploner M,Majewski S,Jablonska S,Pfister HJ,Fuchs PG. Communication: papillomavirus DNA in basal cell carcinomas of immunocompetent patients: an accidental association? J Invest Dermatol 2000; 115: 1248.
  • 43
    Boxman IL,Berkhout RJ,Mulder LH,Wolkers MC,Bouwes Bavinck JN,Vermeer BJ,ter Schegget J. Detection of human papillomavirus DNA in plucked hairs from renal transplant recipients and healthy volunteers. J Invest Dermatol 1997; 108: 71215.
  • 44
    Forastiere A,Koch W,Trotti A,Sidransky D. Head and neck cancer. N Engl J Med 2001; 345: 1890900.
  • 45
    Bova RJ,Quinn DI,Nankervis JS,Cole IE,Sheridan BF,Jensen MJ,Morgan GJ,Hughes CJ,Sutherland RL. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue. Clin Cancer Res 1999; 5: 281019.
  • 46
    Weinberger PM,Yu Z,Haffty BG,Kowalski D,Harigopal M,Sasaki C,Rimm DL,Psyrri A. Prognostic significance of p16 protein levels in oropharyngeal squamous cell cancer. Clin Cancer Res 2004; 10: 568491.
  • 47
    Geisler SA,Olshan AF,Weissler MC,Cai J,Funkhouser WK,Smith J,Vick K. p16 and p53 Protein expression as prognostic indicators of survival and disease recurrence from head and neck cancer. Clin Cancer Res 2002; 8: 344553.
  • 48
    Yuen PW,Man M,Lam KY,Kwong YL. Clinicopathological significance of p16 gene expression in the surgical treatment of head and neck squamous cell carcinomas. J Clin Pathol 2002; 55: 5860.
  • 49
    Scheer M,Prange W,Petmecky K,Schirmacher P,Zoller JE,Kubler AC. Evaluation of her-2/neu amplification/overexpression in OSCC with fluorescence in situ hybridization (FISH) and immunohistochemistry. Mund Kiefer Gesichtschir 2003; 7: 13845.
  • 50
    Yang W,Lin Z,Li L,Zhang G. Expression of VEGF. EGFR, p16 in lip cancers and oral squamous cell carcinomas and their clinic significance. Zhonghua Kou Qiang Yi Xue Za Zhi 2002; 37: 99101.
  • 51
    Kiyota A,Shintani S,Mihara M,Nakahara Y,Ueyama Y,Matsumura T,Todd R,Wong DT. Expression of a truncated epidermal growth factor receptor in oral squamous cell carcinomas. Cancer Lett 2000; 161: 915.
  • 52
    Kreimer AR,Clifford GM,Boyle P,Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev 2005; 14: 46775.
  • 53
    Mellin H,Dahlgren L,Munck-Wikland E,Lindholm J,Rabbani H,Kalantari M,Dalianis T. Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer 2002; 102: 1528.
  • 54
    Gillison ML,Koch WM,Capone RB,Spafford M,Westra WH,Wu L,Zahurak ML,Daniel RW,Viglione M,Symer DE,Shah KV,Sidransky D. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000; 92: 70920.
  • 55
    Kreimer AR,Clifford GM,Snijders PJ,Castellsague X,Meijer CJ,Pawlita M,Viscidi R,Herrero R,Franceschi S. HPV16 semiquantitative viral load and serologic biomarkers in oral and oropharyngeal squamous cell carcinomas. Int J Cancer 2005; 115: 32932.
  • 56
    Mork J,Lie AK,Glattre E,Hallmans G,Jellum E,Koskela P,Moller B,Pukkala E,Schiller JT,Youngman L,Lehtinen M,Dillner J. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001; 344: 112531.
  • 57
    Hoffmann TK,Arsov C,Schirlau K,Bas M,Friebe-Hoffmann U,Klussmann JP,Scheckenbach K,Balz V,Bier H,Whiteside TL. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer 2006; 118: 198491.
  • 58
    Mellin H,Friesland S,Lewensohn R,Dalianis T,Munck-Wikland E. Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer 2000; 89: 3004.
  • 59
    Wittekindt C,Gultekin E,Weissenborn SJ,Dienes HP,Pfister HJ,Klussmann JP. Expression of p16 protein is associated with human papillomavirus status in tonsillar carcinomas and has implications on survival. Adv Otorhinolaryngol 2005; 62: 7280.
  • 60
    Crusius K,Auvinen E,Steuer B,Gaissert H,Alonso A. The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT. Exp Cell Res 1998; 241: 7683.
  • 61
    Mellin DH,Lindquist D,Bjornestal L,Ohlsson A,Dalianis T,Munck-Wikland E,Elmberger G. P16(INK4a) correlates to human papillomavirus presence, response to radiotherapy and clinical outcome in tonsillar carcinoma. Anticancer Res 2005; 25(6C): 437583.
  • 62
    Aklilu M,Kindler HL,Donehower RC,Mani S,Vokes EE. Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol 2003; 14: 12703.
  • 63
    Liu G,Gandara DR,Lara PN,Jr,Raghavan D,Doroshow JH,Twardowski P,Kantoff P,Oh W,Kim K,Wilding G. A Phase II trial of flavopiridol (NSC #649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res 2004; 10: 9248.
  • 64
    Senderowicz AM. Novel small molecule cyclin-dependent kinases modulators in human clinical trials. Cancer Biol Ther 2003; 2(4 Suppl 1 ): S84S95.
  • 65
    Rocco JW,Li D,Liggett WH,Jr,Duan L,Saunders JK,Jr,Sidransky D,O'Malley BW,Jr. p16INK4A adenovirus-mediated gene therapy for human head and neck squamous cell cancer. Clin Cancer Res 1998; 4: 1697704.
  • 66
    Schrump DS,Chen GA,Consuli U,Jin X,Roth JA. Inhibition of esophageal cancer proliferation by adenovirally mediated delivery of p16INK4. Cancer Gene Ther 1996; 3: 35764.
  • 67
    Wang L,Qi X,Sun Y,Liang L,Ju D. Adenovirus-mediated combined P16 gene and GM-CSF gene therapy for the treatment of established tumor and induction of antitumor immunity. Cancer Gene Ther 2002; 9: 81924.
  • 68
    Modjtahedi H. Molecular therapy of head and neck cancer. Cancer Metastasis Rev 2005; 24: 12946.
  • 69
    Schwartz SR,Yueh B,McDougall JK,Daling JR,Schwartz SM. Human papillomavirus infection and survival in oral squamous cell cancer: a population-based study. Otolaryngol Head Neck Surg 2001; 125: 19.
  • 70
    Parsons JT,Mendenhall WM,Stringer SP,Amdur RJ,Hinerman RW,Villaret DB,Moore-Higgs GJ,Greene BD,Speer TW,Cassisi NJ,Million RR. Squamous cell carcinoma of the oropharynx: surgery, radiation therapy, or both. Cancer 2002; 94: 296780.